One week, three lessons for pharma

Comment icon 0 Comments
The past week in pharma was one of those times when just setting the news items alongside one another in the proper order can tell someone... Read more

When a pharma spokesman advocates value-based pricing

Comment icon 0 Comments
The Forbes columnist and pharma cheerleader, John La Mattina, left Pfizer in 2008 as their R&D head with a $22.6 million package after... Read more

Less research training in medical school? That's actually good

Comment icon 0 Comments
In Sunday's Health section of the Inquirer, reporter Ilene Raymond Rush interviewed the dean of Temple's medical school, Arthur Feldman. The... Read more

Which long-term road for GlaxoSmithKline

Comment icon 0 Comments
GlaxoSmithKline (GSK), the British pharmaceutical company with U.S. operations in the Philadelphia area, reported 2015 first quarter earnings... Read more

Drug pricing: The problem and some band-aids

Comment icon 0 Comments
Two stories surfaced this week that provide more examples of how increasing drug prices have gotten totally out of hand. In the first one... Read more

Self-dealing physicians and a bad trade deal

Comment icon 0 Comments
The costs of health care and affordable access to it are made worse by high drug prices that keep rising many times faster than the cost living... Read more

Two questionable ways to develop new drugs

Comment icon 0 Comments
A substantial and growing number of people working in pharma R&D are painfully aware that the industry's “strategic partnering”... Read more

Can polio cure cancer? If it's one dose and done, will pharma try it?

Comment icon 0 Comments
This is definitely a week when the media's spotlight has been shining on cancer. Each evening between Monday and Wednesday, PBS has been running... Read more